Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

GenSci142

Phase 1Small molecule

Changchun GeneScience Pharmaceutical Co., Ltd.

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

RandomizedNot yet recruiting

RandomizedPhase 1

Not yet recruiting

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Single Ascending Dose

NCT07302035

Q2 2027

Phase 1Not yet recruiting

Randomized

NCT07663838

Clinical

Trials by Indication[1]

Single Ascending Dose1 trial

A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese Women

Not yet recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 1·NCT07302035·30 enrolled

Randomized1 trial

A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)

Not yet recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 1·NCT07663838·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for GenSci142. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GenSci142 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GenSci142. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Changchun GeneScience Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Changchun GeneScience Pharmaceutical Co., Ltd.

Related News